(CercleFinance.com) – Bayer today announced that new data from its radiology portfolio will be presented at the European Congress of Radiology (ECR), taking place July 13-17 in Vienna, Austria .
In particular, the laboratory will present its preclinical data on the new development compound gadoquatrane, which is currently in phase II development.
Gadoquatrane exhibits high stability as well as high relaxivity – a key property for use in contrast-enhanced magnetic resonance imaging (MRI) – with the potential to allow for a significantly lower gadolinium (Gd) dose.
Another focus is on clinical data on Bayer Gadovist’s MRI contrast agent (gadobutrol), investigating the clinical effectiveness of a reduced dose of gadobutrol compared to a standard dose of gadoterate in patients undergoing MRI of the contrast-enhanced central nervous system (CNS).
Bayer will also present its research exploring the potential of deep learning to optimize the delivery of contrast media. “AI can help manage the growing workload of radiologists and their teams, ultimately striving to improve patient care,” the lab says.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
